TABLE 4.

Overall survival based on 6-month delta-BMI change

	N	5-years (%)	Univariate		Multivariate
			HR (95 % CI)	p value	HR (95 % CI)	p value
Age (years)				0.042
<50	237	92.7	1		1
≥50	428	85.9	1.82 (1.01–3.27)		1.15 (0.56–2.37)	0.71
Ethnicity				0.021
Non-hispanic	194	82.2	1		1
Hispanic	471	90.8	0.55 (0.32–0.92)		0.65 (0.35–1.20)	0.17
Pre-treatment BMI				0.06
<30	206	84.5	1		1
≥30	459	90.3	0.62 (0.37–1.03)		1.19 (0.62–2.28)	0.60
Hypertension				0.92
No	297	88.4	1
Yes	368	88.4	0.98 (0.58–1.63)
Diabetes mellitus				0.38
No	453	88.0	1
Yes	212	89.3	0.78 (0.44–1.37)
Hypercholesterolemia				0.61
No	500	88.4	1
Yes	165	88.4	0.86 (0.47–1.56)
Histologic subtype				<0.001
Endometrioid	551	94.1	1		1
Non-endometrioid	114	62.0	8.86 (5.25–15.0)		2.06 (1.01–4.20)	0.048
Grade				<0.001
1–2	517	94.8	1		1
3	148	65.6	7.88 (4.62–13.4)		2.20 (0.97–5.01)	0.06
Stage				<0.001
I–II	521	95.8	1		1
III–IV	144	65.8	14.3 (7.56–26.8)		5.56 (2.04–15.1)	0.001
Postoperative chemotherapy				<0.001
None	489	95.7	1		1
Yes	176	69.0	10.6 (5.74–19.7)		1.61 (0.66–3.96)	0.30
Postoperative radiotherapy				<0.001
None or ICBT alone	518	91.6	1		1
WPRT ± ICBT	147	79.4	3.01 (1.80–5.02)		1.13 (0.60–2.14)	0.70
Delta-BMI change				<0.001
<7.5 % lossa	272	95.7	1		1
<7.5 % gain	201	90.3	1.78 (0.78–4.06)		2.02 (0.87–4.70)	0.10
7.5–14.9 % loss	61	70.0	6.72 (2.90–15.6)		4.19 (1.73–10.2)	0.001
7.5–14.9 % gain	20	67.6	5.03 (1.58–16.0)		3.33 (1.01–11.1)	0.049
≥15 % loss	19	59.1	14.4 (5.22–39.9)		5.39 (1.83–15.9)	0.002
≥15 % gain	12	66.7	10.3 (3.50–30.3)		3.50 (1.08–11.3)	0.036

Log-rank test for univariate analysis, and a Cox proportional hazard regression model for multivariate analysis. Covariates entered in the final model were the variables with p < 0.10 in univariate analysis. Significant p values are shown in bold

^aIncluding cases with no interval BMI change

BMI body mass index, 5-years (%) 5-year rate, HR hazard ratio, CI confidence interval, ICBT intracavitary brachytherapy, WPRT whole pelvic radiotherapy